If semaglutide (Wegovy/Ozempic) was the first wave and tirzepatide (Zepbound/Mounjaro) was the second, retatrutide is shaping up to be the third. The early data suggests it could be the most powerful weight-loss peptide yet. But "most powerful" and "best" aren't the same thing.
What makes retatrutide different
Semaglutide activates one receptor: GLP-1. Tirzepatide hits two, GLP-1 and GIP. Retatrutide (also known as LY3437943, developed by Eli Lilly) goes further. It's a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously.
The glucagon receptor is what matters here. Glucagon is the hormone your body releases to raise blood sugar during fasting. It also ramps up energy expenditure and promotes fat oxidation, telling your body to burn stored fat for fuel. By adding glucagon receptor agonism on top of GLP-1 and GIP's appetite-suppressing effects, retatrutide attacks weight loss from both directions: you eat less and you burn more.
The phase 2 trial results
The phase 2 trial, published in the New England Journal of Medicine in 2023, enrolled 338 adults with obesity. Participants received one of several doses of retatrutide or placebo as a once-weekly subcutaneous injection for 48 weeks.
The weight loss numbers by dose:
- Placebo group: -2.1% body weight change
- 1 mg dose: -8.7%
- 4 mg dose (escalated from 2 mg): -17.1%
- 4 mg dose (escalated from 4 mg): -17.1%
- 8 mg dose: -22.8%
- 12 mg dose: -24.2%
At the highest dose, participants lost nearly a quarter of their body weight in under a year. Over 90% of those on the 8 mg and 12 mg doses hit at least 10% weight loss, and about 26% of the 12 mg group lost 30% or more.
For context, bariatric surgery typically produces 25-30% weight loss. Retatrutide is the first injectable peptide to come close to those numbers in a clinical trial.
How it compares to semaglutide and tirzepatide
Comparing across separate trials always comes with caveats. Different patient populations, trial designs, and endpoints can skew the picture. That said, the numbers are hard to ignore:
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Mechanism | GLP-1 agonist | Dual GLP-1/GIP agonist | Triple GLP-1/GIP/glucagon agonist |
| Brand names | Wegovy, Ozempic | Zepbound, Mounjaro | None yet (investigational) |
| Peak weight loss (trial) | ~15% at 68 weeks | ~22.5% at 72 weeks | ~24.2% at 48 weeks |
| Trial phase | Approved (phase 3 complete) | Approved (phase 3 complete) | Phase 3 (ongoing) |
| Administration | Once-weekly injection | Once-weekly injection | Once-weekly injection |
| FDA approved for weight loss | Yes (June 2021) | Yes (November 2023) | No |
| Common side effects | Nausea, vomiting, diarrhea | Nausea, vomiting, diarrhea | Nausea, vomiting, diarrhea |
The number worth paying attention to: 24.2% weight loss in 48 weeks versus tirzepatide's 22.5% at 72 weeks. Retatrutide appears to work faster and may achieve greater total loss, though we need longer-term data to confirm that.
The glucagon receptor advantage
The third mechanism, glucagon receptor agonism, is what separates retatrutide from everything else on the market. Most weight-loss drugs work by reducing caloric intake. Glucagon receptor activation does something different: it increases how many calories your body burns at rest.
In preclinical and early clinical data, glucagon receptor agonism has been linked to:
- Increased resting energy expenditure. Your body burns more calories even when you're sedentary.
- Better hepatic fat oxidation. Your liver processes and burns fat more efficiently, which matters a lot for people with non-alcoholic fatty liver disease (NAFLD).
- Reduced liver fat. In the phase 2 trial, retatrutide reduced hepatic steatosis dramatically. Some participants saw near-complete resolution of fatty liver.
That liver fat finding may end up being as important as the weight-loss data. NAFLD affects roughly 30% of the global population and has limited treatment options right now. A drug that can meaningfully address both obesity and fatty liver disease would be a big deal.
Why you can't get it yet
Despite the strong phase 2 results, retatrutide is not approved or commercially available. As of early 2026, Eli Lilly is running multiple phase 3 trials under the TRIUMPH program, testing retatrutide in larger and more diverse patient populations with longer follow-up.
This matters because phase 2 trials are designed to find the right dose and get an early signal on efficacy. Phase 3 is the real test. These trials are larger (thousands of participants versus hundreds), longer, and more rigorous. There are plenty of drugs that looked great in phase 2 but ran into problems in phase 3, whether from unexpected safety signals, weaker efficacy in broader populations, or manufacturing issues.
The honest assessment
The phase 2 weight loss numbers exceed anything from approved medications, the speed of response is notable, and the liver fat reduction adds a real secondary benefit. The triple-agonist mechanism makes biological sense and has good preclinical support.
But there's a lot we still don't know:
- Long-term safety. 48 weeks of data in 338 people is not enough to catch rare adverse events. The glucagon receptor component raises theoretical concerns about blood sugar elevation and muscle loss that need monitoring over longer periods.
- Weight regain. Like semaglutide and tirzepatide, retatrutide will almost certainly require ongoing use to maintain results. We don't have data yet on what happens when people stop.
- Cardiovascular outcomes. Semaglutide has proven cardiovascular benefits from the SELECT trial. Tirzepatide's cardiovascular outcomes trial is underway. Retatrutide is behind on this.
- Real-world tolerability. GI side effects were common in the phase 2 trial, especially at higher doses. How well patients tolerate this drug over years of use is an open question.
The most likely timeline puts FDA approval somewhere in late 2026 or 2027, assuming the phase 3 trials go well. Regulatory timelines slip often, so take that with a grain of salt.
The bottom line
Is retatrutide better than semaglutide and tirzepatide? The early data says it has the potential to deliver more weight loss through a more complete mechanism. Suppressing appetite while also increasing energy expenditure is a real step forward pharmacologically.
But potential and proven are different things. Semaglutide and tirzepatide have years of phase 3 data, millions of real-world patients, and established safety profiles. Retatrutide has one phase 2 trial. It's promising, but it's early.
If you're considering weight-management options today, focus on what's available and proven. If retatrutide's phase 3 results hold up, it could become the most effective injectable weight-loss therapy available.
Sources
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. (STEP 1)
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(4):327-340. (SURMOUNT-1)
- Sanyal AJ, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024;390(4):311-319.
- Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. J Clin Invest. 2022;132(8):e154785.
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Retatrutide is an investigational drug that has not been approved by the FDA or any regulatory agency for any indication. Always consult with a qualified healthcare provider before starting, stopping, or changing any medication or treatment plan.